Catalio Capital Management
New York, New York, United StatesFounded 2020
Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public, and credit markets. It backs breakthrough biomedical technology companies founded by scientist-entrepreneurs, spanning drugs, devices, diagnostics, data, tools, and healthcare services.
43% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (5 deals in the last 12 months vs 14 prior). Average disclosed round size is $94.6M (across 69 rounds with reported amounts).
Portfolio
68
Fund Size
$400M
Top Stage
Series B
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
77 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Somethings | Series A | $19.2M | Feb 2026 |
 ProSomnus | Unknown | $38M | Jan 2026 |
| CClaris Bio | Series B | — | Jan 2026 |
| KKailera | Series B | $600M | Oct 2025 |
| CCartography | Series B | $67M | Oct 2025 |
 Leo Cancer Care | Series C | $40M | Sep 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Visby Medical | Growth | $55M | Jun 2025 |
 GlycoEra | Series B | $130M | May 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
| IImbria | Unknown | $57.5M | Apr 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
| IImbria | Series B | $57.5M | Jan 2025 |
| AAlentis | Series D | $181.4M | Nov 2024 |
 Prognomiq | Series D | $34M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
| EElektrofi | Series C | $112.3M | Oct 2024 |
 Orasis | Series D | $78M | Oct 2024 |
| OORASIS Pharmaceuticals | Unknown | $78M | Oct 2024 |
 Superluminal Medicines | Series A | $120M | Sep 2024 |
| SSuperluminal | Series A | — | Sep 2024 |
| PProto Axiom | Series B | $20M | Aug 2024 |
 Insightec | Growth | $150M | Jun 2024 |
 AVAVA | Series B | $35M | Jun 2024 |
Page 1 of 4
Top Co-Investors
RA Capital Management12 shared
Alexandria Venture Investments9 shared
Eli Lilly and Company9 shared
T. Rowe Price8 shared
Logos Capital7 shared
OrbiMed7 shared
F-Prime Capital7 shared
Polaris Partners7 shared
SR One6 shared
Novo Holdings A/S6 shared
Rock Springs Capital6 shared
Marshall Wace6 shared
ARCH Venture Partners6 shared
Mubadala Ventures6 shared
Fidelity Investments5 shared
General Catalyst5 shared
Eventide Asset Management5 shared
Surveyor Capital5 shared
Deep Track Capital5 shared
Cormorant Asset Management5 shared
Last updated: 9 September 2026